Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 1/20 | 0.30 |
| ▸ | FLT4 | P35916 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | RARB | P10826 | 1/20 | 0.30 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18313104 | 0.95 | EPHA2 (0.32) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| SCHEMBL22331788 | 0.92 | CNR2 (0.36) | — | |
| SCHEMBL18313225 | 0.92 | CNR2 (0.36) | — | |
| SCHEMBL22331873 | 0.89 | CNR2 (0.32) | — | |
| SCHEMBL18313299 | 0.88 | EPHA2 (0.33) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| SCHEMBL18313216 | 0.87 | EPHA2 (0.31) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| SCHEMBL22331680 | 0.87 | EPHA2 (0.31) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| SCHEMBL18313689 | 0.86 | CNR2 (0.38) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| SCHEMBL22331682 | 0.86 | EPHA2 (0.41) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| SCHEMBL18306063 | 0.86 | EPHA2 (0.41) | EPHA2FLT4GSK3BRARBTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10435403-B2 | Positive allosteric modulators of muscarinic M2 receptor | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-08 | — | — | US | disclosed |
| US-10435403-B2 | Positive allosteric modulators of muscarinic M2 receptor | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-08 | — | — | US | disclosed |
| US-20180297994-A1 | POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC M2 RECEPTOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-10-18 | — | — | US | disclosed |
| WO-2016198342-A1 | POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC M2 RECEPTOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180297994-A1 | POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC M2 RECEPTOR | CHRM2, CHRM1, CHRM3 | EPHA2 1876/4885FLT4 1955/4885GSK3B 3525/4885 |
| US-10435403-B2 | Positive allosteric modulators of muscarinic M2 receptor | CHRM2, CHRM1, CHRM3 | EPHA2 1876/4885FLT4 1955/4885GSK3B 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.